Healthcare / Drug Manufacturers - Specialty & GenericShanghai
$13.88
-0.22 (-1.56%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 24% · confianza 25%
FCF escenarios
weak_data · normalized FCF $433.5M · quality 77.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
46/100
C
Piotroski
4/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
16/100
SEC 0%
Sin guardar todavía.
Market Cap
$6.3B
P/E
15.4x
↓EV/EBITDA
7.3x
↓ROE
6.8%
↑Gross Margin
51.9%
↑Debt/Equity
0.01
↓TradingView lightweight chart
Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2022–2025 · 3 años de histórico normalizado
Revenue CAGR
-5.4%
FCF CAGR
+21.6%
FCF margin
11.7%
FCF / Net income
0.95x
Latest source
Provider fallback
Margin decomposition
Último año: revenue $3.44B · net income $421.2M · FCF $401.6M
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Income Statement | |||||
| Revenue | $3.44B | $3.44B | $3.98B | $4.46B | $4.07B |
| Net Income | $421.2M | $421.2M | $508.9M | $521.3M | $350.0M |
| EBITDA | $698.7M | $698.7M | $805.4M | $836.3M | $600.7M |
| EPS | 0.93 | 0.93 | 1.12 | 1.15 | 0.77 |
| Gross Margin | 51.9% | 51.9% | 56.6% | 58.8% | 56.0% |
| Operating Margin | 10.9% | 10.9% | 13.0% | 13.5% | 8.6% |
| Net Margin | 12.2% | 12.2% | 12.8% | 11.7% | 8.6% |
| Balance Sheet | |||||
| Debt/Equity | 0.01 | 0.01 | 0.02 | 0.03 | 0.03 |
| Current Ratio | 4.65 | 4.65 | — | — | — |
| Cash Flow | |||||
| Free Cash Flow | $401.6M | $401.6M | $469.0M | $433.5M | $223.2M |
| Returns | |||||
| ROE | 6.8% | 6.8% | 8.6% | 9.1% | 6.6% |
| Valuation | |||||
| P/E | 15.42 | 15.42 | 11.96 | 12.98 | 20.23 |
| EV/EBITDA | 7.33 | 7.33 | 6.26 | 7.12 | 10.39 |
| P/B | 1.02 | 1.02 | 1.02 | 1.18 | 1.33 |
| Growth & Yield | |||||
| Revenue Growth | -13.5% | -13.5% | -10.8% | 9.7% | — |
| EPS Growth | -17.0% | -17.0% | -2.6% | 49.4% | — |
| Dividend Yield | 2.5% | 2.5% | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Leverage & Liquidity
3Y implied EPS CAGR
9.8%
EPS terminal req.
$1.23
Spread vs growth
-26.8%
5Y implied EPS CAGR
9.9%
EPS terminal req.
$1.49
Spread vs growth
-26.9%
10Y implied EPS CAGR
9.9%
EPS terminal req.
$2.40
Spread vs growth
-26.9%
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Total return
+3.9%
Start / end P/E
12.2x → 14.9x
EPS bridge
1.12 → 0.93
Residual
-3.8%
Simple additive decomposition: total return = EPS growth contribution + P/E multiple contribution + dividend contribution + explicit residual. The residual captures cross-terms, buybacks/share-count effects, FX, special dividends, data noise and methodology mismatch so the bridge always reconciles.